MeSH term
Frequency | Condition_Probility | Humans | 68 | 0.0 |
Interleukin-1/genetics | 5 | 7.0 |
Risk | 2 | 0.0 |
Aged | 9 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Female | 31 | 0.0 |
Gene Frequency | 11 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Haplotypes | 4 | 0.0 |
Interleukin-1/*genetics | 37 | 45.0 |
Male | 24 | 0.0 |
Middle Aged | 18 | 0.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 46 | 0.0 |
Sialoglycoproteins/*genetics | 8 | 12.0 |
Adult | 21 | 0.0 |
Base Sequence | 12 | 0.0 |
DNA Primers | 5 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Genotype | 21 | 0.0 |
Phenotype | 3 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
*Polymorphism, Genetic | 13 | 0.0 |
Retrospective Studies | 3 | 0.0 |
Hela Cells | 4 | 0.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Models, Genetic | 2 | 0.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Time Factors | 2 | 0.0 |
Trans-Activation (Genetics) | 3 | 0.0 |
Trans-Activators/*metabolism | 3 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Transfection | 3 | 0.0 |
*Viral Envelope Proteins | 2 | 4.0 |
*Viral Proteins | 2 | 1.0 |
Polymorphism, Genetic | 13 | 0.0 |
Pregnancy | 3 | 0.0 |
Receptors, Interleukin-1/*genetics | 2 | 25.0 |
Amino Acid Sequence | 4 | 0.0 |
Animals | 15 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Chromosomes, Human, Pair 2/genetics | 3 | 2.0 |
Cloning, Molecular | 2 | 0.0 |
Exons | 4 | 0.0 |
Gene Order | 2 | 4.0 |
Introns | 3 | 0.0 |
Mice | 7 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Multigene Family/*genetics | 2 | 1.0 |
Sequence Alignment | 3 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Chromosomes, Human, Pair 2/*genetics | 2 | 1.0 |
Adolescent | 4 | 0.0 |
Child | 3 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Risk Factors | 4 | 0.0 |
Case-Control Studies | 7 | 0.0 |
Cells, Cultured | 3 | 0.0 |
Comparative Study | 14 | 0.0 |
Homozygote | 5 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Binding Sites | 7 | 0.0 |
Cell Line | 5 | 0.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Confidence Intervals | 5 | 1.0 |
Alleles | 12 | 0.0 |
Linkage Disequilibrium | 6 | 0.0 |
Odds Ratio | 5 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Intercellular Adhesion Molecule-1/genetics | 2 | 6.0 |
Tumor Necrosis Factor-alpha/genetics | 3 | 1.0 |
Chi-Square Distribution | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
Cytokines/*genetics | 2 | 1.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Heterozygote | 4 | 0.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 5 | 0.0 |
Genetic Markers | 4 | 0.0 |
Haplotypes/*genetics | 2 | 1.0 |
Interleukin-6/*genetics | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
*Multigene Family | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
CCAAT-Enhancer-Binding Proteins | 4 | 2.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Protein Binding | 4 | 0.0 |
*Antiretroviral Therapy, Highly Active | 2 | 0.0 |
CD4 Lymphocyte Count | 2 | 0.0 |
HIV Infections/*drug therapy/genetics | 2 | 28.0 |
HIV-1/*genetics | 2 | 0.0 |
RNA, Viral/blood | 2 | 0.0 |
T-Lymphocyte Subsets | 2 | 1.0 |
Viral Load | 2 | 0.0 |
Viremia/*genetics | 2 | 100.0 |
Prospective Studies | 2 | 0.0 |
Tandem Repeat Sequences | 2 | 1.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Genome, Human | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Chromosomes, Artificial, Yeast/genetics | 2 | 1.0 |
DNA Primers/genetics | 3 | 0.0 |
Species Specificity | 4 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
Prognosis | 2 | 0.0 |
Protein Precursors/*genetics | 2 | 1.0 |
Sequence Tagged Sites | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Swine/*genetics | 2 | 1.0 |
*Genes, Structural | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Chromosomes, Human, Pair 2 | 2 | 1.0 |
Sialoglycoproteins/genetics | 2 | 6.0 |
